Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine + famotidine + naproxen vs loratadine + famotidine + oxycodone for Peg-G-CSF–induced bone pain during chemotherapy
IRCT20250125064508N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of loratadine, famotidine, naproxen and oxycodone in cancer and ostealgia (2 arms), sponsored by Tehran University of Medical Sciences. Started Feb 2025; status: completed.
02
Drugs
loratadinefamotidinenaproxenoxycodone
03
Conditions
cancerostealgia
Beyond the preview
Go deeper on IRCT20250125064508N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250125064508N1.